What is Signatera?

What is Signatera™?

The Signatera™ test is highly sensitive. It is a personalised molecular residual tumour (MRT) test that uses circulating tumour DNA (ctDNA) in the blood for analysis. Signatera is designed individually for each patient to help identify tumour recurrence well before standard imaging procedures.

Signatera teszt

Molecular residual tumour is a different

By using the Signatera™ test, early detection of MRI has become an effective tool for improving cancer treatment outcomes.

MRT tests ctDNA, a cell-free DNA that can be detected and measured in blood.
Accurate identification of ctDNA in the body can be used to determine whether tumour cells are present in the organelle, even after treatment.
MRT detection with Signatera differs from traditional applications of ctDNA (therapy selection, asymptomatic tumour screening) because it uses a personalised genetic test based on the patient’s unique tumour mutation pattern.
Vérvétel a Signatera teszthez

How does Signatera™ work?

Signatera™ is a personalised, tumour-specific, MRI follow-up test. A single analysis of tissue and blood samples allows the determination of a unique tumour mutation profile.

The Signatera™ MRD test examines tiny pieces of ctDNA during each follow-up blood sample. Patients who test positive for ctDNA in the Signatera™ test are more likely to develop a worsening condition.

The applicability of the ctDNA test:
  • Symptom-free cancer screening
  • Molecular residual disease status
  • Monitoring early relapse
  • Monitoring the effectiveness of teraphy

Signatera has been validated for several tumour types

The Signatera™ test can be used for all somatic tumour types.

Signatera™ can help manage the care of patients with tumours


Useful results: colon tumour stage II-III

Interpretation of the test

ctDNA high risk

Use of direct imaging techniques (PET/MRI) to determine the location of the tumour while it is still operable

>97% of patients can have their tumour recur

ctDNA low risk

Continuing the monitoring

Between 12 and 14% of patients may have a recurrence. For patients who remain negative 2 years after treatment, the risk is reduced to 3%.